Millions of Medicare beneficiaries who depend on prescription drugs could see faster decisions on prior authorization requests under a proposed federal rule now open for public comment. The Centers for Medicare and Medicaid Services published the proposal on April 14, 2026, and the comment window closes June 15, 2026. The rule would cap standard prior authorization decisions at 72 hours and urgent decisions at 24 hours, while requiring drug plans to report how often they approve, deny, and overturn requests.
What the proposed rule would change for drug approvals
The proposed rule, designated CMS-0062-P, would extend electronic prior authorization requirements to prescription drugs covered under Medicare Part D. CMS stated the rule sets decision deadlines of no later than 24 hours for urgent requests and 72 hours for standard requests, framing those timelines as part of broader efforts to speed access and reduce administrative burden in its press materials. Plans would also need to publish data on approval rates, denial reasons, appeal outcomes, and how long decisions actually take.
Those 24-hour and 72-hour windows may sound familiar. Existing Part D guidance already applies the same timeframes to coverage determinations that do not involve exceptions. The new proposal would formalize those clocks specifically for prior authorization on drugs and tie them to electronic processing standards built on FHIR-based technology, the same interoperability framework CMS has been pushing across the health care system.
Under CMS-0062-P, Part D sponsors would have to support electronic prior authorization transactions through standardized application programming interfaces. According to the agency’s overview of its interoperability policies, the goal is to let prescribers initiate and track prior authorization directly from their electronic health record systems, rather than relying on fax, phone calls, or proprietary web portals. That technical shift is meant to reduce back-and-forth delays that can leave patients waiting at the pharmacy counter.
The rule also layers on transparency requirements. Plans would need to publicly post, in a machine-readable format, metrics such as the percentage of prior authorization requests approved, denied, or partially approved; average and median decision times; and rates at which denials are overturned on appeal. CMS argues that this kind of plan-level reporting could help beneficiaries and prescribers compare how different plans handle utilization management, potentially influencing enrollment choices.
The drug-focused proposal builds on an earlier final rule, CMS-0057-F, which addressed prior authorization for medical items and services under Medicare Advantage, Medicaid, and other programs. That 2024 rule’s compliance timeline begins primarily in 2026, meaning plans are already adjusting to new electronic standards for non-drug authorizations just as this drug-specific proposal arrives. CMS portrays the two rules as complementary pieces of a single interoperability strategy, rather than isolated regulatory moves.
What remains uncertain about enforcement and impact
Several questions hang over the proposal. CMS has not published data showing how long Medicare drug plans currently take to process prior authorization requests on average. Without that baseline, it is difficult to measure whether the 72-hour and 24-hour caps represent a meaningful acceleration or simply codify existing practice. The agency’s own Part D guidance already sets the same timeframes for coverage determinations, raising the question of what practical gap this rule fills beyond adding electronic processing mandates and transparency requirements.
No drug plan has made public statements in the available record about operational costs or staffing demands the rule would create. The Federal Register notice outlining the proposal does not yet reflect submitted comments, so the range of industry and patient advocacy positions is still forming. CMS has also not released denial or appeal rate data tied to existing Part D timeframes, which would help gauge whether faster clocks alone address the real friction points patients face.
One plausible pressure point is how plans classify requests. Facing a hard 72-hour cap on standard cases and a tighter 24-hour clock for urgent ones, plans and prescribers may disagree more often about what qualifies as “urgent,” potentially shifting disputes from the pharmacy counter to the paperwork itself. If plans interpret urgency narrowly, some beneficiaries could still experience delays even when prescribers see a clinical need for faster turnaround.
Enforcement mechanics also remain somewhat opaque. While CMS can audit plans and impose corrective actions or sanctions, the proposal does not spell out in granular detail how missed electronic prior authorization deadlines would be tracked or penalized. The effectiveness of the rule may depend on how aggressively the agency monitors compliance and whether public reporting alone creates enough reputational pressure to change behavior.
For beneficiaries, the impact will likely hinge on execution. If electronic tools work as intended and plans meet the proposed timeframes, patients could see fewer last-minute surprises at the pharmacy and quicker resolution when a drug requires prior approval. If technical integration lags or reporting data are hard for consumers to interpret, the changes could feel more like a back-end systems upgrade than a visible improvement in access.
With the comment period open through mid-June, stakeholders still have an opportunity to shape the final contours of CMS-0062-P. Patient advocates may press for clearer enforcement provisions and stronger safeguards around urgent requests, while plans may seek flexibility on implementation timelines and reporting details. How CMS balances those competing priorities will determine whether the proposed rule becomes a modest refinement of existing policy or a more substantial shift in how Medicare drug prior authorization works in practice.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
